Ambrx Biopharma, Inc.
AMAMDelisted Mar 7, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001990550
Ambrx Biopharma, Inc. was delisted on Mar 7, 2024; its insiders filed their last Form 4 on Mar 7, 2024; 68 institutions reported holding it in 13F filings for Q4 2023, worth $912.7M in total; no superinvestor held it.
Q3 2022 vs. Q2 2022
How the institutions holding Ambrx Biopharma, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 14 | 16 | +2 |
| Shares | 17.1M | 16.7M | −461.7K (−2.7%) |
| Value | $45.4M | $18.0M | −$27.4M (−60.3%) |
New holders (4)
Institutions that held Ambrx Biopharma, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Royal Bank of Canada | 42,453 | $46.0K | 0.00% |
| Susquehanna International Group, LLP | 19,220 | $21.0K | 0.00% |
| Citadel Advisors LLC | 12,116 | $13.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 42 | $0 | 0.00% |
Sold out (2)
Institutions that held Ambrx Biopharma, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Octagon Capital Advisors LP | 122,800 | $325.0K |
| Norges Bank | 62,396 | $165.3K |